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Abstract
HTRA1 is a highly conserved serine protease which has been implicated in suppression of epithelial-to-mesenchymal-
transition (EMT) and cell motility in breast cancer. Its prognostic relevance for breast cancer is unclear so far. Therefore, we
evaluated the impact of HTRA1mRNA expression on patient outcome using a cohort of 131 breast cancer patients as well as
a validation cohort including 2809 publically available data sets. Additionally, we aimed at investigating for the presence of
promoter hypermethylation as a mechanism for silencing the HTRA1 gene in breast tumors. HTRA1 downregulation was
detected in more than 50% of the breast cancer specimens and was associated with higher tumor stage (p = 0.025). By
applying Cox proportional hazard models, we observed favorable overall (OS) and disease-free survival (DFS) related to high
HTRA1 expression (HR= 0.45 [CI 0.23–0.90], p = 0.023; HR = 0.55 [CI 0.32–0.94], p = 0.028, respectively), with even more
pronounced impact in node-positive patients (HR= 0.21 [CI 0.07–0.63], p = 0.006; HR= 0.29 [CI 0.13–0.65], p = 0.002,
respectively). Moreover, HTRA1 remained a statistically significant factor predicting DFS among established clinical
parameters in the multivariable analysis. Its impact on patient outcome was independently confirmed in the validation set
(for relapse-free survival (n = 2809): HR = 0.79 [CI 0.7–0.9], log-rank p = 0.0003; for OS (n = 971): HR = 0.63 [CI 0.48–0.83], log-
rank p = 0.0009). In promoter analyses, we in fact detected methylation of HTRA1 in a small subset of breast cancer
specimens (two out of a series of 12), and in MCF-7 breast cancer cells which exhibited 22-fold lower HTRA1 mRNA
expression levels compared to unmethylated MDA-MB-231 cells. In conclusion, we show that downregulation of HTRA1 is
associated with shorter patient survival, particularly in node-positive breast cancer. Since HTRA1 loss was demonstrated to
induce EMT and cancer cell invasion, these patients might benefit from demethylating agents or histone deacetylase
inhibitors previously reported to lead to HTRA1 upregulation, or from novel small-molecule inhibitors targeting EMT-related
processes.
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Introduction
The serine protease HTRA1 (Prss11) belongs to the family of
high temperature requirement A {HTRA1} proteins. All mem-
bers of this family consist of a highly conserved protease domain
and one or more PDZ domains, exhibiting high structural
complexity [1–3]. Usually, flat-disk-like trimeric structures
(HTRA1) or higher order oligomers (e.g. DegP) are formed. The
bacterial homologue DegP appears to have a dual role as a
chaperone at normal temperature and as a protease at elevated
temperatures [4]. While the physiological function of human
HTRA1 remains largely unclear to this end, it was shown to be
involved in the pathogenesis of various diseases such as osteoar-
thritic cartilage [5,6], preeclampsia [7] or CARASIL (cerebral
autosomal recessive arteriopathy with subcortical infarcts and
leukoencephalopathy) [8,9].
Due to its ability to attenuate cell motility [10], growth [11,12]
and invasiveness [11,13], HTRA1 is also thought to act as a tumor
suppressor. Accordingly, downregulation of HTRA1 expression
has been reported for various cancer types such as ovarian [12]
and endometrial cancer [13,14] compared to non-malignant
tissue. In the breast, HTRA1 expression is prominent in normal
ductal glands, whereas its expression is distinctly reduced or even
lost in tumor tissues of patients with ductal carcinoma in situ
(DCIS) or invasive breast carcinoma [15]. Low HTRA1 expres-
sion was found to be associated with poor survival in mesothelioma
[16] and hepatocellular carcinoma [17], and has been related to
poor response to cytotoxic chemotherapy in ovarian and gastric
cancer [18,19]. He et al. [20] suggested a role for HTRA1 in
programmed cell death demonstrating a decrease in X-linked
inhibitor of apoptosis protein (XIAP) in ovarian cancer cells
dependent on HTRA1 serine protease activity. A proapoptotic
function of HTRA1 was also apparent following detachment of
epithelial cells. Thus, as a consequence of HTRA1 loss, resistance
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to anoikis (detachment-induced apoptosis) may contribute to
tumor cell dissemination and invasion in metastatic cancer [21].
A variety of substrates such as extracellular matrix proteins are
known to be cleaved by secreted HTRA1 [22,23]. In addition,
intracellular HTRA1 was found to co-localize and associate with
microtubules through its PDZ domain. Since enhanced expression
of HTRA1 attenuated cell motility, whereas HTRA1 loss
promoted cell motility, a function of HTRA1 in modulating the
stability and dynamics of microtubule assembly has been assumed
[10]. Increased motility and invasiveness are also characteristics of
epithelial-to-mesenchymal transition (EMT). In breast cancer,
HTRA1 loss was in fact accompanied by the acquisition of
mesenchymal features as recently shown by Wang et al. [15].
Applying siRNA techniques in the immortalized breast epithelial
cell line MCF10A, an inverse correlation of reduced HTRA1
levels with increased expression of mesenchymal markers, higher
growth rate and increased migration or invasion was observed
[15]. Potentially relevant for anti-cancer therapy, this epithelial-to-
mesenchymal transition process also activated ATM and DNA
damage response pathways and thus, may further result in poor
response to chemotherapy [15].
Taken together, loss of function of HTRA1 may lead to
dysregulation of important cellular functions and contribute to
tumorigenesis. So far, the basis of HTRA1 downregulation in
cancer is unclear, but loss of heterozygosity (LOH) or epigenetic
modulations have been postulated as possible mechanisms [12,15].
Here, we show downregulation of HTRA1 mRNA expression in
a relevant number of breast cancers derived from a cohort of 131
early stage breast cancer patients, validated by public data sets of
2809 cases. To evaluate a possible role of CpG-hypermethylation
in causing HTRA1 downregulation in breast tumors, we subse-
quently analyzed a set of tumor specimens in addition to breast
cancer cell lines by applying bisufite-sequencing techniques.
Patients and Methods
Ethics Statement
The study has been approved by the institutional ethical
committee of Radboud University Nijmegen Medical Centre, The
Netherlands.
Patients
A series of 131 patients with unilateral, resectable breast cancer,
who underwent surgery of their primary tumor between 1986 and
1996, were selected according to the availability of frozen tissue in
the tumor bank of the Department of Laboratory Medicine of the
Radboud University Nijmegen Medical Centre. This bank
contains frozen tumor tissue from patients with breast cancer,
obtained from five hospitals of the Comprehensive Cancer Centre
East in the Netherlands. After surgical resection of the primary
tumor, representative areas of the tumor tissues were selected
macroscopically by a pathologist and immediately snap-frozen in
liquid nitrogen [24]. Estrogen receptor (ER) and progesterone
receptor (PR) levels were measured by a ligand binding assay at
the Department of Laboratory Medicine of the Radboud
University Nijmegen. Histological grades of the tumors were
determined according to Bloom–Richardson criteria, and tumor
stage was classified according to the TNM classification system.
The clinical data were collected retrospectively. Patients had no
previous diagnosis of carcinoma, no distant metastases at time of
diagnosis and no evidence of disease within one month after
primary surgery. Furthermore, patients receiving neo-adjuvant
therapy or with carcinoma in situ only had been excluded from
this series. Surgery consisted of modified radical mastectomy for
93 patients (71%) or breast conserving treatment for 38 patients
(29%). Postoperative radiotherapy (n = 100; 76.3%) was adminis-
tered to the breast after incomplete resection, breast conserving
treatment, or regional lymph node infiltration. Adjuvant therapy
was administered according to guidelines at that time. 61 patients
(47%) had received no further treatment. 50 patients (38%)
received endocrine therapy, 20 patients (15%) received chemo-
therapy including three cases in combination with endocrine
therapy. Axillary lymph node dissection was carried out in all
patients. Lymph node metastasis was observed in 60 (46%) cases.
Lymph node involvement was not known in 19 (14.5%) cases.
Patient age at diagnosis ranged from 31 to 85 with a median age of
62 years. Follow-up data was available for all patients with the
exception of two exact death dates.
Quantification of HTRA1 Expression
Total RNA from fresh-frozen breast cancer tissue samples was
isolated and reverse-transcribed as published previously [25].
HTRA1 mRNA expression was determined by TaqMan real
time PCR using the TaqMan Gene expression assay
Hs01016151_m1 purchased from Applied Biosystems (Darmstadt,
Germany). cDNA was diluted 1:30 and 3 ml of the diluted cDNA,
15 ml of TaqManH Universal PCR Master Mix, 1.5 ml TaqMan
Gene expression assay and 10.5 ml of H2O were pipetted onto a
96well QPCR plate (Peqlab, Erlangen, Germany). The qPCR
assays were run on a TaqMan ABI PRISM 7700 Sequence
Detection System (Applied Biosystems) according to the manu-
facturer’s protocol. All samples were measured in duplicates.
cDNA of an ovarian carcinoma and a breast cancer sample were
included in all runs as calibrator samples. Normalization to human
glucose-6-phosphate-dehydrogenase (h-G6PDH) as appropriate
housekeeping gene for breast cancer studies was performed as
previously described [26]. The ratio between relative HTRA1
mRNA expression quantities and absolute h-G6PDH housekeeping
molecule numbers, adjusted to the sample with the lowest HTRA1
expression, was used for all further calculations and statistical
analyses.
Cell Lines
Breast cancer cell lines MCF-7 (estrogen receptor-positive) and
MDA-MB-231 (estrogen receptor-negative) were purchased from
American Type Culture Collection (ATCC) (Manassas, VA, USA)
and cultured in RPMI 1640 supplemented with penicillin G
(100 U/ml), streptomycin (100 mg/ml), L-glutamine and 10%
fetal calf serum (Invitrogen, Paisley, UK) at 37uC in a humidified
atmosphere containing 5% CO2 [27] Cells were routinely checked
to be free of mycoplasma. DNA or RNA was extracted from
approx. 106 cells which had been harvested in a non-confluent
state. DNA was prepared using the Genomic DNA Puregene
Purification Kit (Qiagen, Hilden, Germany). For preparation of
RNA, the RNeasy kit (Qiagen) was used according to the
manufactures protocol for animal cells. cDNA synthesis was
performed using the 1st Strand cDNA Synthesis Kit for RT-PCR
(AMV) (Roche, Indianapolis, USA) to transcribe 1 mg of RNA
each. cDNA was diluted 1:5 and 1:20, respectively, and triplicates
of each dilution (3 ml) were pipetted onto a 96well QPCR plate
(Peqlab, Erlangen, Germany) together with 15 ml of TaqManH
Universal PCR Master Mix and 1.5 ml TaqMan Gene expression
assay for HTRA1 (Hs01016151_m1) or HPRT (Hs99999909_m1),
respectively, in a final volume of 30 ml. Assays were run in a
TaqMan ABI PRISM 7700 Sequence Detection System (Applied
Biosystems). HPRT was chosen as housekeeping gene for
normalization of HTRA1 expression data in the cell lines. Relative
HTRA1 mRNA expression ratios (calculated from the ratio of
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HTRA1 and HPRT expression quantities and adjusted to a
calibrator sample) were used for further statistical analyses.
Bisulfite Sequencing
Sodium bisulfite conversion of (un)methylated cytosine was
performed using the Epitect Bisulfit kit (Qiagen) and 500 ng of
sample DNA. PCR was performed with 3 ml of bisulfite-converted
DNA, 0.4 ml AmpliTaq Gold polymerase, 5 ml GeneAmp Buffer
10x with MgCl2 (Applied Biosystems), 2 ml MgCl2 (25 mM), 5 ml
dNTP (2 mM), 2 ml each of forward and reverse Primer (10 pmol/
ml) and 30.6 ml H2O. Three sets of primers, covering the region
2560 to +526 relative to the mRNA start site (Accession No.
NG_011554.1), were designed by help of MethPrimer software
(www.urogene.org/cgi-bin/methprimer) and are listed in Table
S1. Sequencing of the PCR products was carried out on a Genetic
Analyser 3130xl (Applied Biosystems, Darmstadt, Germany) using
Big Dye technology (Applied Biosystems).
The amplified fragments which had shown DNA-methylation in
bisufite sequencing analysis, were subcloned using the TOPO-TA
cloning kit and One Shot Top10F’ competent cells (Invitrogen,
Karlsruhe, Germany). Inserts of clones were sequenced using M13
primers.
Statistical Analyses
Statistical analyses were carried out using SPSS 17.0 (SPSS Inc.
Chicago, IL, USA) and R version 2.11.1 (R Foundation for
Statistical Computing, Vienna, Austria). Correlation of relative
expression values with clinical/biochemical data were computed
with the Spearman-Rho method. Difference in HTRA1 expression
between groups defined by clinical parameters was examined by
Mann-Whitney-U-Test or Kruskal-Wallis-Test, depending on the
number of compared groups. Overall survival (OS) and disease-
free survival (DFS) were considered as long-term endpoints. OS
was defined as the time from surgery until death from any cause
and DFS was defined as the time from surgery to the first
incidence of disease recurrence (local or distant) or death. The Cox
proportional hazard model was used to assess univariate and
multivariable explanatory ability of the clinical or molecular
parameters with respect to OS and DFS. Survival rates were
estimated using the Kaplan–Meier method. Differences between
survival curves were tested using the logrank test. Ninety-five
percent confidence intervals (95% CI) were provided for relevant
effect estimates such as hazard ratios (HR). All statistical tests were
conducted two-sided and a p-value,0.05 was considered to
indicate statistical significance. Optimal cut-off values of quanti-
tative predictive values regarding patient prognosis were obtained
with the R-program maxstat.test [28]. This function takes into
account the issue of cut-off values derived by multiple testing and
computes adjusted p-values.
An online database consisting of gene expression data (Affyme-
trix HGU133A and HGU133+2 microarrays) and survival
information downloaded from GEO was used to validate HTRA1
expression with respect to the relapse-free survival (RFS) and OS
in 2809 and 971 breast cancer patients, respectively. Distant-
metastasis-free survival (DMFS) was analyzed in 311 patients.
Version 2012 was used (last update 2013.02.26) applying a follow-
up time of 15 years (see ref. [29]). The Affymetrix-ID of the
HTRA1 probe is 201185_at.
This study adheres to the REMARK criteria for tumor marker
studies [30].
Results
Patient Characteristics
A cohort of 131 patients with unilateral breast cancer was
collected for this study. Clinical data are listed in Table 1. The
median follow-up time was 92.8 months, ranging from 3 to 169
months. Recurrence or death was observed in 38% (50 out of 131)
and 29% (37 out of 129) of the cases, respectively (combined
events of recurrence and/or death encompassed 58 (44%) cases).
The Kaplan Meier estimates for the 5- and 10-year overall survival
(OS) rates in the entire patient cohort were 85% (63,2% standard
error SE) and 66% (64.9%), respectively. 5- and 10-year
recurrence-free times were obtained in 75% (64.0%) and 54.5%
(65.2%) of the patients, respectively. Combined disease-free
survival rates (DFS, neither death nor recurrence) were estimated
to 71.5% (64.0%) for 5 years and to 50% (65.0%) for 10 years.
For the lymph node-positive subgroup, the following outcome
Table 1. HTRA1 mRNA expression levels in a cohort of 131
breast cancer patients.
Variable N=131a
HTRA1 Expression
Medianb (IRc) p
Age 0.271d
,50 23 48 (54)
.50 108 37 (51)
Menopausal status 0.337d
pre2/perimenopausal 28 45 (47)
postmenopausal 103 37 (56)
Lymph node status 0.439e
negative 52 41 (47)
1–3 lymph nodes 43 48 (63)
4–9 lymph nodes 11 34 (41)
.9 lymph nodes 6 19 (45)
Tumor stage (pT) 0.025e
1 39 53 (58)
2 72 40 (49)
3+4 18 20 (26)
Grading 0.587d
1+2 49 45 (60)
3 46 30 (49)
Estrogen receptor 0.672d
negative 37 32 (65)
positive 91 43 (54)
Progesterone receptor 0.219d
negative 51 31 (56)
positive 77 45 (56)
Surgery 0.320d
breast conserving 38 47 (60)
mastectomy 93 32 (49)
aDue to missing data the sum of values may be lower than 131.
bMedian of relative HTRA1 mRNA expression values after normalization to
glucose-6-phosphate-dehydrogenase (h-G6PDH) expression and adjustment to
the sample with lowest HTRA1 expression.
cIR: interquartile range.
dMann-Whitney-U test.
eKruskal-Wallis test.
doi:10.1371/journal.pone.0060359.t001
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rates were observed: OS: 82% (65.1%) for 5 years and 68%
(66.8%) for 10 years; DFS: 68% (66.1%) for 5 years and 46%
(67.4%) for 10 years.
HTRA1 Expression in Groups Defined by
Clinicopathologic Parameters
Relative HTRA1 mRNA expression ratios in the breast cancer
specimens ranged from 1 to 308-fold compared to the sample
exhibiting the lowest HTRA1 expression, the median expression
level was 38. Comparison of the expression data between patient
groups defined by clinical and histomorphological parameters
(Table 1) revealed a statistical significant difference only for pT
categories, indicating a decrease in HTRA1 mRNA levels with
increasing tumor stage (p= 0.025). Interestingly, HTRA1 expres-
sion levels did not exceed relative values higher than 55 in the
presence of very high ER concentrations .400 fmol/mg protein.
HTRA1 Expression and Patient Outcome
We next assessed the impact of HTRA1 mRNA expression on
patient survival using OS and DFS as outcome variables. With
respect to an optimized cut-off value of $48, deduced by means of
the program R (Figure S1), 56 (43%) tumor specimens showed
high HTRA1 expression and 75 (57%) low expression. High
HTRA1 mRNA expression levels were found to be associated with
favorable OS and DFS (Figure 1A and B), showing a significantly
reduced risk for recurrent disease and/or death in the entire
patient cohort (HR=0.45 [CI 0.23–0.90], p = 0.023 for OS;
HR=0.55 [CI 0.32–0.94], p = 0.028 for DFS; Table 2 and 3).
Moreover, HTRA1 expression was maintained as a statistically
significant factor which predicted outcome (DFS) independent
from nodal status when tested among the established clinical
factors age, tumor stage, nodal involvement and nuclear grading
(binary variables) in the multivariable analysis (Table 4).
Validation Set
Public data sets of breast cancer patients derived from GEO
expression data were used for validation [29]. We could confirm a
statistically significant effect of high HTRA1 mRNA expression
(based on Affymetrix HGU133A and HGU133+2 microarrays) on
patient outcome: In 2809 patients with 15-year-follow up, a
HR=0.79 [CI 0.7–0.9], log-rank p= 0.0003, was defined for the
relapse-free survival (RFS). The data set available for the 15-year-
OS included 971 patients and yielded a HR=0.63 [CI 0.48–
0.83], log-rank p= 0.0009 (Figure S2).
Subgroup Analysis
Stratification of patients by clinicopathological parameters
revealed a more pronounced impact of HTRA1 mRNA expression
in the node-positive subgroup of our patient cohort (n = 60). We
observed a considerable lower risk for death (5-fold) or disease
progression (3-fold) with higher HTRA1 concentrations:
HR=0.21 [CI 0.07–0.63], p= 0.006 for OS; HR=0.29 [CI
0.13–0.65], p = 0.002 for DFS (Figure 2A and B). In the
multivariable model including tumor stage and adjuvant treat-
ment, HTRA1 expression was confirmed as a clinically relevant
parameter predicting OS or DFS (Table 5 and 6). Adjusted for
therapy mode (none, endocrine, chemotherapy), the impact of
HTRA1 expression remained statistically significant as well: OS:
HR (HTRA1) = 0.23 [CI 0.07–0.72]; p = 0.012; DFS: HR
(HTRA1) = 0.29 [CI 0.13–0.67]; p = 0.004.
On the other hand, no positive effect of HTRA1 expression was
apparent in mostly untreated node-negative patients (HR=1.24
[CI 0.52–2.98], p = 0.663 for DFS). Since 53 out of our 60 patients
with node-positive disease had received endocrine (n = 35) and/or
chemotherapy (n= 18), the observed effects of HTRA1 appear to
be largely related to the patient subgroup which is adjuvantly
treated. These results are also reflected by the publically available
data set which showed greater benefit from endocrine therapy
(n= 743) at high HTRA1 expression (HR=0.66 [CI 0.5–0.89],
log-rank p= 0.006 for RFS), while HTRA1 expression had no
Figure 1. Patient outcome as a function of HTRA1mRNA expression in breast cancer patients. A. Overall survival (n = 129). B. Disease-free
survival (n = 131).
doi:10.1371/journal.pone.0060359.g001
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statistically significant impact on RFS in 933 systemically
untreated patients (HR=0.84 [CI 0.68–1.05], log-rank p= 0.123).
Methylation Analysis
To investigate HTRA1 promoter hypermethylation as a possible
mechanism of HTRA1 downregulation in breast tumors, we
analyzed the extent of CpG methylation in a region of approx.
1000 bp including the HTRA1 transcription start point as
illustrated in Figure 3A. Two sets of six tumor samples displaying
high and low expression of HTRA1, respectively, were chosen from
breast cancer specimens of our study. Additionally, we analyzed
two breast cancer cell lines showing different HTRA1 expression
levels. Relevant promoter methylation was detected only in two
out of the 12 tumor specimens, exhibiting low relative HTRA1
expression levels of 2.5 and 2.7, and in the MCF-7 cell line
(Figure 3B and C). Subcloning of the tumor-derived amplicons
(tumors #8 and #9) revealed DNA methylation in these tumor
specimens within a region of nt 2537 to 2293 upstream of the
mRNA start point. Patients #8 and #9 both showed disease
Table 2. Univariate Cox proportional hazard ratios for OS
with respect to clinical parameters and HTRA1 mRNA
expression levels.
Variable N=129
Number
of events
Hazard Ratio
(95% CI) pa
HTRA1 expression
low 73 25 1 0.023
high 56 12 0.45 (0.23–0.90)
Age
,50 23 8 1 0.444
.50 106 29 0.74 (0.34–1.61)
Menopausal status
Pre-/peri- 28 10 1 0.276
postmenopausal 101 27 0.82 (0.57–1.18)
Lymph node status
negative 51 13 1 0.005
1–3 lymph nodes 43 10 0.90 (0.40–2.07)
4–9 lymph nodes 11 3 1.41 (0.40–4.95)
.9 lymph nodes 6 5 5.77 (2.02–16.51)
unknown 18
Tumor stage (pT)
1 39 10 1 0.308
2 71 20 1.19 (0.56–2.55)
3+4 17 7 2.09 (0.79–5.52)
unknown 2
Nuclear grading
1+2 49 15 1 0.896
3 45 13 0.95 (0.45–2.00)
unknown 35
Estrogen receptor
negative 35 8 1 0.387
positive 91 28 1.42 (0.64–3.13)
unknown 3
Progesterone receptor
negative 49 12 1 0.435
positive 77 24 1.32 (0.66–2.64)
unknown 3
Adjuvant therapy
none 60 19 1 0.850
endocrine only 49 13 1.07 (0.40–2.87)
chemotherapy 20 5 0.87 (0.31–2.45)
aUnivariate Cox regression analysis; 95% CI, 95% confidence interval; OS, overall
survival with endpoint death of any cause.
doi:10.1371/journal.pone.0060359.t002
Table 3. Univariate Cox proportional hazard ratios for DFS
with respect to clinical parameters and HTRA1 mRNA
expression levels.
Variable N=131
Number
of events
Hazard Ratio
(95% CI) pa
HTRA1 expression
low 75 37 1 0.028
high 56 21 0.55 (0.32–0.94)
Age
,50 23 11 1 0.329
.50 108 47 0.72 (0.37–1.39)
Menopausal status
Pre-/peri- 28 14 1 0.200
postmenopausal 103 44 0.82 (0.61–1.11)
Lymph node status
negative 52 20 1 0.023
1–3 lymph nodes 43 20 1.22 (0.64–2.27)
4–9 lymph nodes 11 4 1.19 (0.41–3.47)
.9 lymph nodes 6 5 4.82 (1.77–13.14)
unknown 19
Tumor stage (pT)
1 39 16 1 0.148
2 72 31 1.18 (0.65–2.17)
3+4 18 11 2.26 (0.97–4.55)
unknown 2
Nuclear grading
1+2 49 22 1 0.489
3 46 23 1.23 (0.69–2.21)
unknown 36
Estrogen receptor
negative 37 17 1 0.983
positive 91 40 1.01 (0.57–1.78)
unknown 3
Progesterone receptor
negative 51 21 1 0.443
positive 77 36 1.24 (0.72–2.12)
unknown 3
Adjuvant therapy
none 61 25 1 0.730
endocrine only 50 23 1.01 (0.56–1.86)
chemotherapy 20 10 1.36 (0.63–2.92)
aUnivariate Cox regression analysis; 95% CI, 95% confidence interval; DFS,
disease-free survival with endpoints recurrence and/or death.
doi:10.1371/journal.pone.0060359.t003
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recurrence after 75 and 34 months, respectively; Patient #8 died
of disease. Almost complete methylation was observed in MCF-7
cells within a stretch of 43 potential CpG sites (position –537 to
2203 relative to mRNA start point). Compared with these cells,
MDA-MB-231 breast cancer cells displayed no detectable
methylation accompanied by a 22-fold higher HTRA1 mRNA
expression (Figure 3C and D). According to the data of Wang
et al. [15], treatment with demethylating agents does not further
increase HTRA1 transcripts in MDA-MB-231 cells. Thus, it is
reasonable that all relevant CpG sites have been examined and
found unaffected in this cell line.
Discussion
Numerous studies revealed downregulation of the serine
protease HTRA1 in cancer. In particular, studies in ovarian and
endometrial cancer reported reduced HTRA1 protein levels in
59% [12] and 57% [13] of the cases. In these tumors, absence of
HTRA1 expression has also been associated with more aggressive
tumor phenotypes and higher grading. HTRA1 expression was
also reduced or entirely lost in six studied breast cancer tissues and
five human breast cancer cell lines as reported by Wang et al. [15].
In the present study, we have investigated the presence of HTRA1
transcripts in a panel of 131 breast cancer specimens by qPCR.
Our patient cohort displayed a wide range of relative HTRA1
mRNA expression levels. Lower HTRA1 mRNA values were
indeed observed in patients exhibiting more aggressive clinical
characteristics like high grading or high lymph node infiltration
($4 lymph nodes), however, a statistically significant association
was obtained only between low HTRA1 mRNA expression and
higher tumor stage (see Table 1).
Evaluating the impact of HTRA1 expression on breast cancer
outcome, we could show favorable survival (OS and DFS) in
relation to high HTRA1 mRNA expression. Moreover, HTRA1
revealed to be a survival-related factor providing independent
prognostic information in the multivariable model. We subse-
quently validated our data using publically available data sets
based on Affymetrix HGU133A and HGU133+2 microarrays
[29], which provided relapse-free survival (RFS) data of 2809
Figure 2. Patient outcome in node-positive breast cancer patients as a function of HTRA1mRNA expression. A. Overall survival (n = 60).
B. Disease-free survival (n = 60). Multiple testing performed with the R-package maxstat.test [28] is provided.
doi:10.1371/journal.pone.0060359.g002
Table 4. Multivariable Cox regression analysis for DFS.
Univariate Cox-Regression Multivariable Cox-Regression
Variable HR (95% CI) p HR (95% CI) p
HTRA1expression (low/high) 0.55 (0.32–0.94) 0.028 0.46 (0.23–0.92) 0.028
Nodal status (negative/positive) 1.39 (0.79–2.46) 0.256 2.12 (1.07–4.22) 0.032
Tumor stage (pT1+2/pT3+4) 2.11 (1.09–4.09) 0.027 1.29 (0.50–3.33) 0.597
Age at diagnosis (,50 ys/.50 ys) 0.72 (0.37–1.39) 0.329 0.54 (0.25–1.17) 0.119
Nuclear grading (G1+2/G3) 1.23 (0.69–2.21) 0.489 1.21 (0.59–2.51) 0.606
Number of patients in multivariable analysis: n = 80; number of events of recurrence and/or death in multivariable analysis: 38.
For both analyses, binary variables are used; HR, hazard ratio; 95% CI, 95% confidence interval.
DFS: disease-free survival with endpoints recurrence and/or death.
doi:10.1371/journal.pone.0060359.t004
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breast cancer patients and OS data of 971 patients within a follow
up time of at least 15 years. Consistent with our results, the
validation set showed better patient survival associated with high
HTRA1 mRNA expression. Taking into account the relative
heterogeneous nature of this panel of up to 2809 breast cancer
cases, the impact of HTRA1 was less pronounced (HR=0.79 for
RFS), but high statistical significance was obtained (log-rank
p= 0.0003). Best cut-off points in this analysis were slightly above
the median HTRA1 expression level, compatible with our
calculated optimized cut-off value. Thus, HTRA1 mRNA expres-
sion appears as a robust marker for breast cancer outcome
supported by two different methodologies to assess transcript
levels. Furthermore, correlation of HTRA1 mRNA and protein
expression has been reported for a number of cancers such as
endometrial and ovarian cancer as well as for melanoma cell lines
[11,12,31], suggesting equal relevance of mRNA compared to
protein measurement. This is also supported by coincident
downregulation of mRNA and protein expression levels of
HTRA1 in Syrian hamster kidney after prolonged estrogenization
[32].
In subgroup analyses, we observed the most pronounced effect
of HTRA1 proficiency in node-positive breast cancer. It might be
reasonable to assume a higher relevance of HTRA1 expression
especially in breast cancer patients with lymph node involvement,
because these patients usually receive adjuvant therapy due to
their greater risk of disease progression [33]. Accordingly, we
demonstrated that 88% of our node-positive patients had been
treated with endocrine and/or chemotherapy, whereas only three
out of our 52 node-negative patients were adjuvantly treated.
Hence, together with our data obtained in the validation set, these
data may support previous results in gastric and ovarian cancer
[18,19] which have linked HTRA1 proficiency to better thera-
peutic responsiveness indicating that HTRA1 is a predictive
marker. Similarly, in a breast cancer study, HTRA1 was one
among a panel of three markers which predicted response to
doxorubicin-based chemotherapy [34]. In contrast, low HTRA1
expression was previously shown to trigger EMT in breast cancer
cells [15] which is most likely involved in drug resistance [35].
Furthermore, low HTRA1 expression appears to be associated
with more aggressive clinical characteristics. In our breast cancer
patient cohort, we observed reduced HTRA1 expression levels
particularly in patients exhibiting unfavorable clinical features
such as high numbers of affected lymph nodes ($4 lymph nodes;
see Table 1). Because an even greater HTRA1 downregulation in
lymph node metastases compared to the primary sites was evident
in lung cancer [36] and malignant melanoma [11], this strongly
points to a particular benefit for node-positive patients to have
high expression of the tumor suppressor HTRA1.
Interestingly, GEO-data-derived results computed by us for the
10-year-distant-metastasis-free survival (DMFS) in untreated
patients may also point to a ‘‘truly’’ prognostic value of HTRA1
expression regarding the risk of metastasis. By analyzing the ‘‘truly
prognostic data set’’ (n = 311) we found strong association of high
HTRA1 mRNA expression levels with longer DMFS showing a
HR=0.45 [CI 0.31–0.65], log-rank p= 0.0000097 (see Figure S3).
The lower risk of metastasis at high HTRA1 expression levels is
most likely related to the anti-migratory [7,10,21] and proapopto-
tic functions [12,20] described for this serine protease. In
particular, HTRA1 downregulation has been previously shown
to be associated with the metastatic phenotype of melanoma cells,
while HTRA1 expression suppressed growth and matrix invasion
of metastatic cells [11]. Furthermore, stimulation of cancer cell
migration and invasion following HTRA1 inhibition could be
demonstrated in SKOV3 cells [10] and in immortalized breast
epithelial cells [15]. Both studies used siRNA techniques to knock
down HTRA1 expression, while forced HTRA1 expression
attenuated cell migration. A mouse model strongly supports these
data as increased numbers of micrometastases could be found in
the lung of mice after i.v. injection of endometrial cancer cells
expressing HTRA1-siRNA [13].
A particular feature of metastatic breast cancer is activation of
EMT which is known to promote growth, motility and invasion.
Table 5. Multivariable Cox regression analysis* for the risk of death (OS) in node-positive breast cancer patients.
Univariate Cox-Regression Multivariable Cox-Regression
Variable HR (95% CI) p HR (95% CI) p
HTRA1expression (low/high) 0.21 (0.07–0.63) 0.006 0.25 (0.08–0.80) 0.020
Tumor stage (pT1+2/pT3+4) 2.51 (0.93–6.78) 0.070 1.44 (0.48–4.31) 0.511
Adjuvant therapy (no/yes) 0.33 (0.12–0.928) 0.036 0.54 (0.18–1.64) 0.277
*Number of patients in multivariable analysis: n = 60; number of events of death: 18; binary variables are used; HR, hazard ratio; 95% CI, 95% confidence interval; OS,
overall survival with endpoint death of any cause.
doi:10.1371/journal.pone.0060359.t005
Table 6. Multivariable Cox regression analysis* for DFS in node-positive breast cancer patients.
Univariate Cox-Regression Multivariable Cox-Regression
Variable HR (95% CI) p HR (95% CI) p
HTRA1expression (low/high) 0.29 (0.13–0.65) 0.002 0.34 (0.15–0.79) 0.012
Tumor stage (pT1+2/pT3+4) 2.56 (1.15–5.71) 0.021 1.81 (0.79–4.18) 0.162
Adjuvant therapy (no/yes) 0.47 (0.18–1.24) 0.127 0.70 (0.26–1.90) 0.480
*Number of patients in multivariable analysis: n = 60; number of events of recurrence and/or death: 29; binary variables are used; HR, hazard ratio; 95% CI, 95%
confidence interval; DFS, disease-free survival with endpoints recurrence and/or death.
doi:10.1371/journal.pone.0060359.t006
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Downregulation of HTRA1 was indeed shown to stimulate
expression of mesenchymal markers and characteristics in breast
cancer cells [15]. HTRA1 was also shown to regulate TGF-ß
signaling. Decrease of HTRA19s proteolytic activity, e.g. in
CARASIL [9], leads to increased extracellular levels of TGF-ß.
Since TGF-ß is a potent inducer of EMT [37,38], this would speak
in favor of a direct role of HTRA1 in controlling active TGF-ß
levels, thereby suppressing EMT. Targeting EMT-related pro-
cesses downstream of HTRA1 might therefore proof an attractive
new strategy in the treatment of breast cancer. In this context,
Fang et al. very recently introduced a novel inhibitor of TGF-ß
receptor 1, YR-290, which could be demonstrated to markedly
block TGF-ß-mediated EMT and breast cancer cell invasion [39].
Alternatively, new therapeutic strategies may exploit mecha-
nisms to stimulate re-expression of HTRA1, although the basis of
HTRA1 downregulation in cancer cells might be complex.
Overstimulation of the estrogen pathway may contribute to a
decrease in HTRA1 expression as described in a model of Syrian
hamster nephrocarcinogenesis after prolonged estrogenization
[32]. Similarly, we did not see any cases with pronounced HTRA1
mRNA expression in breast cancer samples displaying very high
estrogen receptor values. Epigenetic events have been postulated
as other potential mechanisms to reduce HTRA1 expression levels
in cancer. In particular, Chien et al [12] reported upregulation of
HTRA1 by treatment of ovarian cancer cells with the demethyl-
ating agent deaza-cytidin. Consistent with these findings, promoter
methylation within the HTRA1 gene has been very recently
demonstrated in four out of five breast cancer cell lines [15].
Independently, we have screened a larger region of approx. 1000
bp including the transcription start point for the presence of
HTRA1 methylation. Analyzing the two breast cancer cell lines
MCF-7 and MDA-MB-231, we could define 43 potential CpG
sites (position –537 to 2203 relative to mRNA start) which were
found to be almost fully methylated in MCF-7 cells. In
concordance with the data of Wang et al. [15], we did not detect
significant methylation in this region in MDA-MB 231 cells
exhibiting .20-fold higher HTRA1 mRNA expression compared
to the MCF-7 cell line. These data suggest that the studied
promoter region upstream of the transcription start point is
apparently important for HTRA1 expression. Remarkably, also
two out of six low HTRA1 -expressing tumor samples derived from
our breast cancer cohort showed methylation in a smaller, distal
Figure 3. Methlylation analysis of the HTRA1 promoter. A. Schematic illustration of the studied region covering nucleotides –560 to +526
relative to the transcription start site. The location of amplicons and of highly methylated CpG sites determined in this study is indicated. B.
Methylation status of tumor samples #8 and #9: Potential CpG sites and the results of 13 analyzed clones in the amplicon upstream of the
transcription start site are shown (black circles define methylated sites). The most distant CpG site is located at position 2537, the most proximal site
at position 2293. C. Electropherograms obtained by genomic bisulfite sequencing of MCF-7 und MDA-MB-231 breast cancer cell lines. MCF-7 cells
showed strong methylation of all CpG islands in the ‘‘upstream’’ region (shown here in part) and, as the only sample, in the first seven CpG-islands in
the PCR fragment ‘‘mRNA start’’. Methylated CpG sites are highlighted. No significant methylation was observed in MDA-MB-231 cells. D.
Quantification of HTRA1 mRNA expression in two breast cancer cell lines. Relative HTRA1 expression levels, normalized to HPRT and adjusted to an
ovarian cancer sample as calibrator, are shown in MCF-7 and MDA-MB-231 cells. SD values of two independent experiments are indicated. Mean
difference in expression between both cell lines was 22-fold.
doi:10.1371/journal.pone.0060359.g003
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stretch of this particular region (recent data obtained by Wang
et al. with the MDA-MB-468 cell line suggested that the more
distal CpG sites might in fact be the most relevant ones for
HTRA1 expression [15]). None of the six studied high-expressing
tumors indicated relevant HTRA1 promoter methylation. How-
ever, as only one third of the tumors with HTRA1 downregulation
seemed to show methylation events, such events are likely to
represent only one epigenetic mechanism for regulating HTRA1
expression. Indeed, HTRA1/Prss11 has been previously found to
be a target for histone deacetylase 1 (HDAC1) in mouse and
HTRA1/Prss11 upregulation was reported by HDAC inhibition
[40]. Concordant with these results, Wang et al. [15] demonstrat-
ed upregulation of HTRA1 mRNA in methylation-negative MDA-
MB-231 cells by HDAC inhibitors, while demethylating agents
resulted in increased HTRA1 expression in highly methylated
M4A4 cells. Thus, HTRA1 downregulation in cancer might in
fact be explained by epigenetic mechanisms such as promoter
methylation or histone-deacetylation [15].
Further investigation will be necessary to unravel the regulation
of HTRA1 expression in breast cancer in order to stimulate re-
expression of this tumor-suppressor for the purpose of clinical
intervention, e.g, by HDAC inhibitors or demethylating agents.
With respect to the role of HTRA1 in EMT suppression, breast
cancer patients with low HTRA1 expression might also be suited
for drugs targeting EMT-related processes via inhibition of TGF-ß
signaling [39].
Supporting Information
Figure S1 Determination of the optimal cut-off value for
quantitative HtrA1 mRNA expression levels. The best
cut.off value with respect to patient outcome was obtained with the
R-program maxstat.test [28].
(TIF)
Figure S2 HTRA1 expression and patient outcome in the
validation set. An online database consisting of gene expression
data and survival information downloaded from GEO (Affymetrix
HGU133A and HGU133+2 microarrays) was used for correlation
with outcome within a period of 15 years [29]. A. Relapse-free
survival in 2809 breast cancer patients. Median HTRA1 expression
was 3979. Auto-selected best cut-off used in analysis was 4417. B.
Overall survival in 971 breast cancer patients. Auto-selected best
cut-off used in analysis was 5190.
(PPT)
Figure S3 HTRA1 expression and distant metastasis-
free survival in the truly prognostic data set. An online
database consisting of gene expression data and survival
information downloaded from GEO (Affymetrix HGU133A and
HGU133+2 microarrays) was used for correlation with distant
metastasis-free survival [29]. Survival data of 311 systemically
untreated breast cancer patients for up to 10 years were calculated.
Auto-selected best cut-off used in analysis was 3366.
(PPT)
Table S1 Primer set for bisulfite sequencing.
(DOC)
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